CAMK2D, EIF3K, MPC2, MYL12B, PAM, and SLC35B4, selected from the schizophrenia dataset and TCGA, were reevaluated in CGGA through gene expression in glioma grading and survival curves between patients having high level of gene expression and those having low level of gene expression. This evidence concerns the gene PAM and schizophrenia.